You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 147 No. 1, January 1987 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Low-Dose Autologous In Vitro Opsonized Erythrocytes

Radioimmune Method and Autologous Opsonized Erythrocytes for Refractory Autoimmune Thrombocytopenic Purpura in Adults

Raúl Ambriz, MD; Rodrigo Muñóz, MD; Javier Pizzuto, MD, FACP; Elisa Quintanar; Manuel Morales, MD, FACP; Agustin Avilés, MD

Arch Intern Med. 1987;147(1):105-108.


Abstract



• Adult patients with chronic autoimmune thrombocytopenic purpura (ATP), which proved refractory to various treatments, received a single dose of autologous in vitro opsonized erythrocytes with 100 µg of anti-D IgG. In 1983, 30 of these patients were treated with autologous erythrocytes that had been opsonized and labeled with 25 mCi (740 MBq) of technetium Tc 99m; this treatment was designated as the radioimmune method. Favorable responses were noted in 36% of patients so treated. In 1985, another group of 16 patients with refractory ATP received therapy with autologous opsonized erythrocytes (AOPE) and 55% of these patients showed favorable responses. Five (17%) of the patients treated using the radioimmune method attained a complete, long-term (>35 months) remission of their ATP, and five (31%) of the patients treated using AOPE remained in complete remission over 270 days after cessation of therapy. Major complications were not seen. We concluded that the interaction of macrophages with low-dose AOPE is a successful therapeutic approach in ATP refractory to standard treatment.

(Arch Intern Med 1987;147:105-108)



Author Affiliations



From the Departments of Hematology (Drs Ambriz, Pizzuto, Morales, and Aviles), Nuclear Medicine (Dr Muñóz), and Immunology (Ms Quintanar), General Hospital and Central Blood Bank, National Medical Center, Mexico City.


Footnotes



Accepted for publication April 7, 1986.

Presented in part at the 26th annual meeting of the American Society of Hematology, Miami Beach, Fla, Dec 3, 1984.

Reprint requests to the Department of Hematology, General Hospital and Central Blood Bank, National Medical Center, IMSS, Mexico City 06720, Mexico (Dr Ambriz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy: A Systematic Review
Vesely et al.
ANN INTERN MED 2004;140:112-120.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.